ptcl

Showing 1 - 7 of 7

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

First-line Maintenance Treatment of PTCL With Chidamide.

Recruiting
  • PTCL
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jul 23, 2023

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

PTCL Trial in Long Beach, New Haven, Charlottesville (Azacytidine, Romidepsin, Belinostat)

Recruiting
  • PTCL
  • Long Beach, California
  • +2 more
Mar 1, 2022

PI3Kd Inhibitor, Parsaclisib, CHOP Trial (Parsaclisib, CHOP)

Not yet recruiting
  • PI3Kδ Inhibitor
  • +3 more
  • (no location specified)
Feb 10, 2022

PTCL Trial (YY-20394 treatment)

Not yet recruiting
  • PTCL
  • YY-20394 treatment
  • (no location specified)
Jan 8, 2021

PTCL, Gemcitabine Trial in Jinan

Unknown status
  • PTCL
  • Gemcitabine
    • Jinan, Shandong, China
      Yujie MS JIANG
    Mar 19, 2019

    PTCL, CTCL Trial (Volasertib, Romidepsin)

    Withdrawn
    • PTCL
    • CTCL
    • (no location specified)
    Nov 29, 2016